Bone Research (May 2024)

RUFY4 deletion prevents pathological bone loss by blocking endo-lysosomal trafficking of osteoclasts

  • Minhee Kim,
  • Jin Hee Park,
  • Miyeon Go,
  • Nawon Lee,
  • Jeongin Seo,
  • Hana Lee,
  • Doyong Kim,
  • Hyunil Ha,
  • Taesoo Kim,
  • Myeong Seon Jeong,
  • Suree Kim,
  • Taesoo Kim,
  • Han Sung Kim,
  • Dongmin Kang,
  • Hyunbo Shim,
  • Soo Young Lee

DOI
https://doi.org/10.1038/s41413-024-00326-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Mature osteoclasts degrade bone matrix by exocytosis of active proteases from secretory lysosomes through a ruffled border. However, the molecular mechanisms underlying lysosomal trafficking and secretion in osteoclasts remain largely unknown. Here, we show with GeneChip analysis that RUN and FYVE domain-containing protein 4 (RUFY4) is strongly upregulated during osteoclastogenesis. Mice lacking Rufy4 exhibited a high trabecular bone mass phenotype with abnormalities in osteoclast function in vivo. Furthermore, deleting Rufy4 did not affect osteoclast differentiation, but inhibited bone-resorbing activity due to disruption in the acidic maturation of secondary lysosomes, their trafficking to the membrane, and their secretion of cathepsin K into the extracellular space. Mechanistically, RUFY4 promotes late endosome-lysosome fusion by acting as an adaptor protein between Rab7 on late endosomes and LAMP2 on primary lysosomes. Consequently, Rufy4-deficient mice were highly protected from lipopolysaccharide- and ovariectomy-induced bone loss. Thus, RUFY4 plays as a new regulator in osteoclast activity by mediating endo-lysosomal trafficking and have a potential to be specific target for therapies against bone-loss diseases such as osteoporosis.